Follow-The-Filings

Security

Cytomx Therapeutics Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

7 owners max 0.1% (Steve Cohen - Point72 Ass...)

owners 7
max % 0.1%
tracked value $145M
qoq A 4 R 2

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Steve Cohen - Point72 Asset Management, L.P. 2026 Q1 0.1% Add +0.02 pp 7,875,390 $37M hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Add +0.01 pp 4,138,176 $19M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Add +0.01 pp 3,660,190 $17M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit -0.01 pp 1,560,755 $7M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Reduce 0.00 pp 8,475,584 $36M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 5,406,193 $25M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Reduce -0.02 pp 730,844 $3M hist

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $101.21M $138.1M $76.2M
Gross profit
Gross margin
Net income -$569,000 $31.87M -$17.37M
Net margin * -0.6% 23.1% -22.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $182.94M $107.3M $143.92M
Total non-current assets * $18.86M $13.23M $7.64M
Total assets $201.79M $120.53M $151.57M
Total current liabilities $155.91M $85.77M $46.62M
Total non-current liabilities * $93.33M $35.22M $5.94M
Total equity -$47.45M -$456,000 $99.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$56.04M -$86.23M -$75.59M
Cash from investing -$150.67M $99.7M -$59.74M
Cash from financing $30.23M $7.52M $110.45M
Net change in cash * -$176.48M $20.99M -$24.88M

ownership over time

filing count by report period · click a bar for that quarter’s holders